PTPN11 Mutation Clonal Hierarchy in Acute Myeloid Leukemia.

Area of Science:

• Molecular Biology
• Oncology
• Immunology

Background:

• Protein tyrosine phosphatase non-receptor type 11 (PTPN11) mutations were traditionally viewed as late events in acute myeloid leukemia (AML) development.
• Understanding the precise timing and role of PTPN11 mutations in AML ontogeny is crucial for therapeutic strategies.

Purpose of the Study:

• To investigate the role of PTPN11 mutations as initiating events in acute myeloid leukemia (AML).
• To confirm the co-driver function of PTPN11 mutations in AML pathogenesis.
• To identify novel therapeutic targets in AML subsets with PTPN11 and NPM1 mutations.

Main Methods:

• Employed single-cell DNA sequencing to analyze the origin of PTPN11 mutations.
• Developed and utilized a novel murine model to study the AML phenotype driven by PTPN11 mutations.
• Analyzed patient samples with NPM1 and PTPN11 mutations for immune diversity.

Main Results:

• Identified PTPN11 mutations as initiating events in AML when co-occurring with strong oncogenic drivers, particularly NPM1 mutations.
• Demonstrated that PTPN11 mutations drive an AML phenotype with early expansion of diverse myeloid cells in a murine model.
• Observed immune diversity in AML patient samples with NPM1 and PTPN11 mutations, suggesting potential antigen targets.

Conclusions:

• PTPN11 mutations can act as initiating drivers in AML, especially when partnered with NPM1 mutations.
• The study provides a novel murine model for investigating AML driven by PTPN11 mutations.
• Immune diversity in PTPN11-mutated AML suggests new avenues for immunotherapy in this treatment-resistant patient group.